IQVIA beats Q3 guidance with revenue $4.428B, EPS $3.34, raises 2026 outlook

 

 on strong clinical bookings and AI demand

• Investor takeaway – Q3 revenue, EBITDA and EPS beat high-end guidance, with accelerating organic growth, clinical bookings and margin execution.
• Investor takeaway – biggest positive surprise was $3.2B R&DS net new bookings, best in 4 years and +15% YoY.
• Investor takeaway – key risk is rising pass-through mix and sizeable interest expense obscuring margin, earnings power and free-cash-flow strength.
• Key results – Q3 revenue $4.428B (+8% YoY; ~6% organic), adjusted EPS $3.34 (+11.3% YoY), adjusted EBITDA $1.032B (+8.7% YoY).
• Guidance & outlook – 2026 guidance raised: revenue $17.35–17.5B (+6.4–7.3% YoY), adjusted EBITDA $4.025–4.055B.
• Guidance & outlook – adjusted EPS $12.90–13.00 (+8.2–9.1% YoY), flat EBITDA margin (~23.2%), management sounding confident.
• Growth drivers – R&DS revenue +8.7% YoY (almost 7% organic) on stronger full-service outsourcing and higher win rates.
• Growth drivers – biotech funding up ~85% YoY to $90B YTD.
• Growth drivers – Commercial Solutions revenue +6.9% YoY (4% organic), fourth consecutive quarter and >40% increase in drug launches.
• Problem areas – higher pass-throughs create ~70 bps margin headwind and 70 bps FX headwind in Q4, pressuring growth.
• Margins & profitability – gross margin percentage not disclosed; adjusted EBITDA margin expanded 20 bps in Q3.
• Margins & profitability – ~80 bps improvement from cost containment, internal AI and productivity, offset by pass-through and FX headwinds.
• Other highlights – R&DS backlog $32.6B; next-12-month revenue $9.4B (+10% YoY); last-12-month R&DS bookings $11.7B (+14% YoY, rising five quarters).
• Other highlights – free cash flow $667M (120% of adjusted net income); net leverage 3.45x.
• Other highlights – Q&A focused on AI monetization, bookings/backlog quality, momentum, margins and interest expense run-rate (~$210M expected in Q4).

https://finviz.com/stock?t=IQV&p=d